Novel calculator predicts risk of epilepsy after rare stroke
en-GBde-DEes-ESfr-FR

Novel calculator predicts risk of epilepsy after rare stroke


A practical calculator that predicts the risk of epilepsy after venous stroke is presented in a study from the University of Gothenburg and others. The aim is to improve care for those affected, which are predominantly young adults.
A blood clot in the cerebral venous system (cerebral venous thrombosis) is a rare but important cause of stroke. In Sweden, around 150 individuals are affected each year, typically affecting women between the ages of 20 and 50. One in three patients experiences a seizure during the acute phase. Predicting who is at high or low risk of recurrent seizures, epilepsy, is complicated.
In an international collaboration between fifteen centers across three continents, researchers from Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital have developed a practical calculator that quickly calculates the risk of developing epilepsy at the onset of the disease. The results of the multi-center study are now presented in JAMA Neurology and the tool is made freely available.
Important to predict the aftermath
First author of the study is Erik Lindgren Bogdanoff, researcher at the Section of Clinical Neurosciences, Sahlgrenska Academy at the University of Gothenburg, and Resident Physician in Neurology at Sahlgrenska University Hospital.
“The calculator predicts the risk of epilepsy based on factors that are already available in clinical routine when the person is hospitalized, there is therefore no need for additional tests or investigations,” he says, and he continues:
“For those affected by sinus thrombosis, it is very important to know what the aftermath looks like. Priorly, we have not able to predict what patients have the highest risk of developing epilepsy after cerebral venous thrombosis.” With a high predicted risk of future seizures, preventive medication can be considered in consultation between doctor and patient.
Erik Lindgren Bogdanoff emphasizes that although epilepsy could have negative impact on the quality of life, most people with epilepsy are able to pursue their life normally even with diagnosis of epilepsy. However, without the proper treatment, seizures can be so severe that they require hospitalization. It is hoped that the calculator can be used by physicians worldwide to support treatment decisions or inform patients about risks, and can be used in future studies on preventive treatment with medicine.
Can improve care for young people
The study is based on registry data from the International Cerebral Venous Thrombosis Consortium (ICVTC) and the results have since been confirmed in two additional independent registries: the US ACTION-CVT and the Israeli CVT Study. In total, data from over 2,000 individuals have been analyzed.
“The involvement of research participants, together with extensive international collaboration, has been a prerequisite for obtaining sufficient data and conducting studies despite being a rare disease, which provide results that can be translated into clinical practice. Although the disease itself is relatively rare, it is important to improve care for those affected. The results are a step towards more person-centered care for young people affected by stroke,” says Erik Lindgren Bogdanoff.
The calculator: www.cerebralvenousthrombosis.com
Development and Validation of a Clinical Score to Predict Epilepsy After Cerebral Venous Thrombosis
Erik Lindgren, Liqi Shu, Naaem Simaan, Katarzyna Krzywicka, Maria A. de Winter, Mayte Sánchez van Kammen, Jeremy Molad, Piers Klein, Hen Hallevi, Rani Barnea, Mirjam R. Heldner, Sini Hiltunen, Diana Aguiar de Sousa, José M. Ferro, Antonio Arauz, Jukka Putaala, Marcel Arnold, Thanh N. Nguyen, Christoph Stretz, Turgut Tatlisumak, Katarina Jood, Shadi Yaghi, Ronen R. Leker, Jonathan M. Coutinho
JAMA Neurology
https://doi.org/10.1038/s44318-024-00299-8
Attached files
  • Erik Lindgren Bodganoff, Sahlgrenska Academy at the University of Gothenburg (photo: Josefin Bergenholtz)
  • Erik Lindgren Bodganoff, Sahlgrenska Academy at the University of Gothenburg (photo: Josefin Bergenholtz)
Regions: Europe, Sweden
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement